A Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 (Galcanezumab) in Japanese Patients With Episodic Migraine
Phase of Trial: Phase II
Latest Information Update: 20 Aug 2017
At a glance
- Drugs Galcanezumab (Primary)
- Indications Migraine
- Focus Therapeutic Use
- Sponsors Eli Lilly
- 20 Apr 2017 Results from this trial will be presented at the American Academy of Neurology (AAN) annual meeting 2017, as reported in an Eli Lilly and Company media release.
- 11 Nov 2016 New trial record
- 10 Nov 2016 Status changed from not yet recruiting to recruiting.